Advertisement

Urologie in der Praxis

, Volume 21, Issue 1, pp 10–16 | Cite as

Medikamentöse Therapie des benignen Prostatasyndroms – Chemie oder Pflanzen

  • Mustafa TutalEmail author
Extended Abstract
  • 1 Downloads

Bei der Behandlung von Symptomen des unteren Harntraktes im Rahmen eines benignen Prostatasyndroms ist die medikamentöse Therapie eine rasch wirksame und effektive Therapieoption. Hierfür stehen zahlreiche synthetische Medikamente sowie Phytopharmaka zur Verfügung. Die synthetischen Therapeutika können einerseits in der Behandlung der akuten Symptome und andererseits bei einer nachhaltigen Reduktion der Krankheitsprogression wirksam sein. Bei milden bis moderaten Symptomen können Phytopharmaka eine Beschwerdelinderung bringen, bei nahezu nebenwirkungsfreier Anwendung.

Einleitung

Unter dem Begriff des benignen Prostatasyndroms (BPS) werden im klinischen Alltag verschiedene Symptome des unteren Harntraktes („lower urinary tract symptoms“ [LUTS]), meist verursacht durch eine Blasenauslassobstruktion („bladder outlet obstruction“ [BOO]) im Rahmen einer gutartigen Prostatavergrößerung („benign prostatic enlargement“ [BPE]), zusammengefasst.

Dabei stehen diese Erscheinungen nicht zwingend in...

Drug treatment of benign prostate syndrome: chemicals or plants

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

M. Tutal gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine vom Autor durchgeführten Studien an Menschen oder Tieren.

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

Literatur

  1. 1.
    Gratzke C et al (2015) EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol 67(6):1099–1109CrossRefGoogle Scholar
  2. 2.
    Michel MC, Vrydag W (2006) Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147(Suppl 2):S88–S119CrossRefGoogle Scholar
  3. 3.
    Barendrecht MM et al (2008) Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn 27:226CrossRefGoogle Scholar
  4. 4.
    Chang DF et al (2005) Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 31:664CrossRefGoogle Scholar
  5. 5.
    Oelke M, Höfner K, Berges RR, Jonas U (2002) Medikamentöse Therapie des benignen Prostatasyndroms mit α1-Rezeptorblockern. Urologe A 41:425–441CrossRefGoogle Scholar
  6. 6.
    Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4‑year results from the CombAT study. Eur Urol 57:123–131CrossRefGoogle Scholar
  7. 7.
    Naslund MJ et al (2007) A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther 29:17CrossRefGoogle Scholar
  8. 8.
    McConnell JD, Roehrborn CG, Bautista OM et al (2003) The longterm effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398CrossRefGoogle Scholar
  9. 9.
    Gravas S, Oelke M (2010) Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 28:9–15CrossRefGoogle Scholar
  10. 10.
    Ückert S, Oelke M (2011) Phospho-diesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol 72:197–204CrossRefGoogle Scholar
  11. 11.
    Oelke M, Giuliano F, Mirone V et al (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61:917–925CrossRefGoogle Scholar
  12. 12.
    Oelke M, Giuliano F, Baygani SK et al (2014) Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with Lower Urinary Tract Symptoms (LUTS) suggestive of Benign Prostatic Hyperplasia (BPH): results from a randomised, placebo-controlled study. BJU Int 114:568–575CrossRefGoogle Scholar
  13. 13.
    Gacci M, Corona G, Salvi M et al (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α‑blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61:994–1003CrossRefGoogle Scholar
  14. 14.
    Kaplan SA, Roehrborn CG, Rovner ES et al (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA 296:2319–2328CrossRefGoogle Scholar
  15. 15.
    Chapple CR et al (2013) Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 63:296CrossRefGoogle Scholar
  16. 16.
    Oelke M, Martinelli E (2016) Medikamentöse Therapie des benignen Prostatasyndroms. Urologe 55:81–96CrossRefGoogle Scholar
  17. 17.
    Barkin J, Guimaraes M, Jacobi G et al (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 44:461–466CrossRefGoogle Scholar
  18. 18.
    Casabé A, Roehrborn CG, Da Pozzo LF et al (2014) Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol 191:727–733CrossRefGoogle Scholar
  19. 19.
    Glina S, Roehrborn CG, Esen A et al (2015) Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. J Sex Med 12:129–138CrossRefGoogle Scholar
  20. 20.
    Saller R, Kasper S, Dimpfel W et al (2014) Phytotherapy in geriatrics and gerontology. Forsch Komplementmed 21(Suppl 1):2–18.  https://doi.org/10.1159/000362393 CrossRefPubMedGoogle Scholar
  21. 21.
    Madersbacher S et al (2008) Plant extracts: sense or nonsense? Curr Opin Urol 18:16CrossRefGoogle Scholar
  22. 22.
    Tacklind J et al (2012) Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.cd001423.pub3 CrossRefPubMedGoogle Scholar
  23. 23.
    Bach D (2000) Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH- bedingten Miktionsbeschwerden. Urologe B 40:437CrossRefGoogle Scholar
  24. 24.
    Berges R et al (1995) Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 345:1529CrossRefGoogle Scholar
  25. 25.
    Klippel KF et al (1997) A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol 80:427CrossRefGoogle Scholar
  26. 26.
    Wilt T et al (2000) Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev: Cd001043Google Scholar
  27. 27.
    Wilt T et al (2002) Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev: Cd001044Google Scholar
  28. 28.
    Carraro JC et al (1996) Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 29:231CrossRefGoogle Scholar
  29. 29.
    Safarinejad MR (2005) Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother 5:1CrossRefGoogle Scholar
  30. 30.
    Lopatkin N et al (2005) Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, double-blind, multicenter trial. World J Urol 23:139CrossRefGoogle Scholar
  31. 31.
    Sokeland J et al (1997) Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study. Urologe 36:327CrossRefGoogle Scholar
  32. 32.
    Vahlensieck W et al (2015) Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study. Urol Int 94:286CrossRefGoogle Scholar
  33. 33.
    Morgia G et al (2014) Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate 74:1471CrossRefGoogle Scholar
  34. 34.
    Sokeland J et al (1997) Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Alken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study. Urologe A 36:327CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Urologie, EBU Certified Training CentreKantonsspital WinterthurWinterthurSchweiz

Personalised recommendations